Tadalafil Tablet
Product Images NDC 71610-896

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-896). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0896 06)

Tadalafil USP 10 mg tablets packaging label showing a package of 6 tablets. The label includes storage instructions, manufacturer information (Ajanta Pharma USA Inc., Bridgewater, NJ), and repackaging information by Aphena Pharma, Cookeville, TN. The package is marked RX only and provides the NDC number 71610-896-06.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing change from baseline in IPSS Total Score over 12 weeks comparing Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles). The graph indicates a greater decrease in IPSS score with Tadalafil over time, with statistical significance noted at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing the differences in blood pressure measurements (systolic and diastolic) comparing Tadalafil to placebo over time in hours. The charts display standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure, with data points and error bars plotted across a 96-hour period.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing the effects on systolic blood pressure over 24 hours post-dose. The top graph depicts standing systolic blood pressure changes for Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure changes over the same period for the same two treatments.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph showing changes in systolic blood pressure (mmHg) over time after administration of tadalafil or placebo combined with doxazosin. The x-axis represents time in hours (0 to 12), and the y-axis shows systolic blood pressure changes ranging from -20 to +10 mmHg. Four data series compare tadalafil doses (20 mg) taken at 08:00 or 20:00 with placebo, each matched with 8 mg doxazosin at 08:00.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days. The y-axis indicates concentration, and the x-axis indicates time from 0 to 120 hours, with concentration decreasing over time and a secondary measurement after 96 hours.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period. The graph compares Tadalafil 5 mg tablet and placebo, with the Tadalafil group showing a greater decrease in score over time, indicating improvement. The x-axis represents duration of treatment (weeks) and the y-axis represents change from baseline in IPSS total score.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period, comparing Tadalafil 5 mg and placebo. The graph indicates statistical significance (p<0.01) at multiple time points, with Tadalafil showing a greater reduction in IPSS score over time.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph illustrating least-squares mean change from baseline in weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride. The graph shows data points at 0, 4, 12, and 26 weeks, with Tadalafil/Finasteride demonstrating greater mean reductions over time compared to Placebo/Finasteride. Statistical significance markers (p<0.001 and p<0.05) are noted at various time points.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, showing its characteristic fused ring system and substituents, as depicted in the molecular diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.